Novel current and future therapy options for treatment of dry eye disease

Dry eye disease was redefined by the dry eye workshop (DEWS II) in May 2017. According to the new definition "dry eye is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film and accompanied by ocular symptoms". The current definition encomp...

Full description

Saved in:
Bibliographic Details
Published inDer Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft Vol. 115; no. 2; pp. 100 - 106
Main Author Messmer, E M
Format Journal Article
LanguageGerman
Published Germany 01.02.2018
Subjects
Blepharitis
Cornea
Dry Eye Syndromes - therapy
Humans
Meibomian Glands
Tears
Tear film
Medications
Artificial tears
Ocular surface
Meibomian gland dysfunction
Online AccessGet full text

Cover

More Information
Summary:Dry eye disease was redefined by the dry eye workshop (DEWS II) in May 2017. According to the new definition "dry eye is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film and accompanied by ocular symptoms". The current definition encompasses etiological factors, such as instability and hyperosmolarity of the tear film, ocular surface inflammation and damage as well as a new aspect compared to the former definition, neurosensory abnormalities. Recent and future therapeutic options for dry eye focus on treatment of the aforementioned pathogenetic events. New tear substitutes, medications and devices to stimulate tear production, innovative anti-inflammatory treatment, medications to influence corneal innervation and new methods for treatment of Meibomian gland dysfunction are already available or will be available in the near future.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1433-0423
DOI:10.1007/s00347-017-0608-6